Is there a role for LHRH antagonists in prostate cancer?

ONCOLOGY

Volumn 23, Issue 7, 2009, Pages

  Goodman Jr , Oscar B ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; DEGARELIX; GONADORELIN ANTAGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTHRALGIA; CANCER HORMONE THERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CASTRATION; CHILL; HUMAN; INJECTION SITE REACTION; NOTE; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; URINARY TRACT INFECTION;

ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 67650866234     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (8)

1. Klotz L, Boccon-Gibod L, Shore ND, et al: The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
2. Lin BJ, Chen KK, Chen MT, et al: The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer. Urology 43:834-837, 1994.
3. Lowe FC, Somers WJ: The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostatic cancer. J Urol 137:1000-1002, 1987.
4. Loose DS, Kan PB, Hirst MA, et al: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:1495-1499, 1983.
5. Gsur A, Bernhofer G, Hinteregger S, et al: A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 87:434-437, 2000.
6. Kotake T, Usami M, Akaza H, et al: Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: A multicenter, randomized, controlled trial in Japan. Zoladex Study Group. Jpn J Clin Oncol 29:562-570, 1999.
7. Chung CS, Chen MH, Cullen J, et al: Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology 71:136-140, 2008.
8. Beer TM: Experimental use of GnRH antagonists as second-line hormonal therapy. Rev Urol 6(suppl 7):S33-S38, 2004.